KLOW

KLOW (80mg) — Four-Peptide Skin, Repair and Inflammation Research Blend

KLOW (80mg) is supplied in Australia by Omega Peptides Australia from domestic stock, with same-day dispatch on orders placed before 12pm and an independent certificate of analysis for every batch. Commonly written as KLOW peptide, KLOW blend or KLOW stack, it is a four-peptide blend combining GHK-Cu, BPC-157, TB-500 and KPV in a single vial.

KLOW is a multi-peptide research blend that combines four separately studied peptides in one lyophilised vial: 50mg of GHK-Cu (the copper-binding tripeptide glycyl-L-histidyl-L-lysine first isolated from human plasma), 10mg of BPC-157 (a fifteen-amino-acid pentadecapeptide derived from a gastric protective protein), 10mg of TB-500 (a synthetic peptide based on the actin-binding region of thymosin beta-4) and 10mg of KPV (Lys-Pro-Val, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone), for 80mg of peptide in total. It is often written as KLOW peptide, KLOW blend or klow 80mg, and sometimes described as the GHK-Cu BPC-157 TB-500 KPV blend. The name is a coined product name: GLOW is the three-peptide base blend, and KLOW is the version with KPV added.

KLOW is studied in three main directions: skin and collagen remodelling (driven by GHK-Cu), soft-tissue repair and angiogenesis (BPC-157 and TB-500), and inflammatory signalling (KPV). At the pathway level the four components act through distinct mechanisms, from copper delivery and gene modulation in fibroblasts to growth-factor signalling, actin regulation and inhibition of NF-κB, which is the rationale for combining them in a single research vial.

Omega Peptides Australia supplies KLOW as a high-purity (≥99% HPLC) COA-verified lyophilised powder in a sealed sterile vial. Orders placed before 12pm are dispatched the same day from within Australia, and the Certificate of Analysis for each batch is published in our COA library. Researchers looking to buy the KLOW blend in Australia get verified material and domestic stock with no customs delays.

Key research areas

• Skin and collagen remodelling GHK-Cu has been studied in fibroblast cultures and skin models for its effect on collagen, elastin and glycosaminoglycan synthesis, and on the balance between matrix metalloproteinases and their inhibitors. It is proposed to act by delivering copper to cells, where it is a cofactor for the collagen-crosslinking enzyme lysyl oxidase, and by modulating genes involved in tissue remodelling.
• Wound healing All four components have been investigated in wound models. GHK-Cu has been studied in dermal wound and ulcer models, thymosin beta-4 has progressed through Phase 2 clinical programmes for chronic dermal wounds, and BPC-157 has been examined in rodent skin-wound and burn models.
• Tendon, ligament and muscle repair BPC-157 and TB-500 are the most frequently paired peptides in preclinical connective-tissue research. BPC-157 is proposed to increase fibroblast outgrowth and collagen deposition through FAK-paxillin signalling, while TB-500 regulates the actin cytoskeleton that cells need in order to migrate into an injury site.
• Angiogenesis New vessel formation is a shared endpoint across the blend. BPC-157 activates VEGFR2 and nitric-oxide signalling in endothelial cells, thymosin beta-4 promotes endothelial cell migration and tube formation, and GHK-Cu has been reported to increase VEGF expression in cultured cells.
• Inflammatory signalling KPV is the anti-inflammatory component. It retains the anti-inflammatory activity of alpha-MSH without its pigmentation effects, and has been studied for inhibiting NF-κB activation and reducing inflammatory cytokine production in keratinocytes, intestinal epithelial cells and immune cells.
• Gut and mucosal research KPV is taken up by intestinal epithelial cells through the PepT1 transporter and has been studied in mouse colitis models, while BPC-157 was originally characterised as a gastroprotective peptide. The blend is therefore also used in mucosal inflammation and repair designs.

KLOW in Australia

KLOW is not registered on the Australian Register of Therapeutic Goods, so it is not stocked by Chemist Warehouse, Priceline or other pharmacies. In Australia it is supplied as a research-grade lyophilised vial by domestic research suppliers. Omega Peptides Australia holds KLOW in stock within Australia and dispatches orders placed before 12pm the same business day on tracked domestic delivery, so material arrives in days rather than waiting on an international shipment and customs. Every batch is tested independently and its certificate is published in the COA library before the vial ships.

KLOW is stocked in Australia as a single 80mg vial. Its four components, GHK-Cu, BPC-157, TB-500 and KPV, are each also held individually, as is the three-peptide GLOW blend without KPV.

How KLOW works

Each component of KLOW works through a different mechanism. GHK-Cu binds copper(II) with high affinity and carries it into cells, where copper is required by lysyl oxidase for collagen and elastin crosslinking and by superoxide dismutase for antioxidant defence; in fibroblast studies it also alters the expression of genes governing matrix synthesis, breakdown and repair. BPC-157 activates VEGFR2 and the Akt-eNOS pathway in endothelial cells, increasing nitric-oxide production and angiogenesis, and triggers the FAK-paxillin pathway in fibroblasts, increasing migration and collagen output. TB-500 reproduces the Leu-Lys-Lys-Thr-Glu-Thr-Gln motif of thymosin beta-4 that binds G-actin, regulating cytoskeletal remodelling so that cells can move and divide during repair. KPV, the Lys-Pro-Val tail of alpha-MSH, inhibits NF-κB activation and the downstream production of inflammatory cytokines, and enters epithelial cells through the PepT1 transporter.

The practical difference between KLOW and GLOW is the KPV. GLOW contains the same 50mg of GHK-Cu, 10mg of BPC-157 and 10mg of TB-500 in a 70mg vial; KLOW adds 10mg of KPV to bring the total to 80mg, so it is chosen when a study wants an explicit anti-inflammatory signal alongside the repair and collagen components. Human pharmacokinetic data for the individual peptides are limited, and none of the four is an approved medicine.

Specifications

Available sizes and pricing

KLOW is supplied in a single 80mg vial containing all four peptides in fixed amounts. Buying the same quantities as individual vials (GHK-Cu 50mg at $89.99, BPC-157 10mg at $99.99, TB-500 10mg at $99.99 and KPV 10mg at $79.99) would cost $369.96, so the blend substantially lowers the cost per mg for laboratories that want all four compounds together.

• 80mg vial (GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg) — $149.99 (about $1.87 per mg)

Quality and COA verification

Every batch of KLOW is independently tested by Janoshik Analytical. HPLC confirms purity, and mass spectrometry confirms the identity of each peptide in the blend by matching its measured mass to the expected molecular weight. A Certificate of Analysis is issued for every batch and published in our COA library, where the batch number printed on your vial can be checked against the report. The blend is lyophilised for long-term stability, sealed in a sterile vial and packed in protective packaging for domestic transit.

Frequently bought together

• GHK-Cu (50mg) — $89.99, the copper tripeptide on its own for skin and collagen studies
• BPC-157 (10mg) — $99.99, the single-compound vial for repair models that need more BPC-157
• TB-500 (10mg) — $99.99, the actin-binding peptide for migration and angiogenesis designs
• KPV (10mg) — $79.99, the anti-inflammatory tripeptide as a standalone control

Research guides

• KLOW research guide
• GHK-Cu research guide
• How to store lyophilised peptides
• COA testing explained
• Peptide reconstitution calculator
• Certificates of Analysis library

Frequently asked questions

What is KLOW?
KLOW is the product name for a four-peptide research blend supplied as a single 80mg lyophilised vial. The name is coined rather than chemical: GLOW is the base blend of GHK-Cu, BPC-157 and TB-500, and KLOW is that blend with KPV added. References to the KLOW peptide or KLOW blend mean this specific combination in these fixed amounts.

What is in the KLOW peptide blend?
Each vial contains 50mg of GHK-Cu, the copper-binding tripeptide glycyl-L-histidyl-L-lysine; 10mg of BPC-157, a pentadecapeptide derived from a gastric protective protein; 10mg of TB-500, a synthetic peptide based on the actin-binding region of thymosin beta-4; and 10mg of KPV, the Lys-Pro-Val tripeptide from the C-terminus of alpha-MSH. The total is 80mg of peptide, supplied as lyophilised powder.

What is KLOW also known as?
It is also written as KLOW peptide, KLOW blend, klow 80mg or KLOW 80, and described as the GHK-Cu BPC-157 TB-500 KPV blend. The components have their own aliases: GHK-Cu is called copper peptide, BPC-157 is written BPC 157 or BPC157, TB-500 is written TB500, and KPV is sometimes called the alpha-MSH tripeptide.

How does KLOW work?
Each component acts differently. GHK-Cu delivers copper to cells, supporting lysyl oxidase-dependent collagen crosslinking, and modulates gene expression involved in matrix remodelling. BPC-157 activates VEGFR2 and nitric-oxide signalling and the FAK-paxillin pathway, promoting angiogenesis and fibroblast migration. TB-500 binds G-actin to regulate cytoskeletal remodelling and cell migration. KPV inhibits NF-κB activation, reducing inflammatory cytokine production. The blend lets these signals be studied together.

What does the research show about KLOW?
KLOW has not been studied as a fixed combination in published trials; the evidence relates to its components. GHK-Cu has been reported to increase collagen and glycosaminoglycan synthesis in fibroblasts and to modulate remodelling genes, BPC-157 has been studied across rodent tendon, muscle and gastrointestinal models, thymosin beta-4 has reached Phase 2 clinical programmes in dermal wounds, and KPV has been reported to reduce inflammation in colitis and skin models. All four remain investigational.

Can I buy KLOW at Chemist Warehouse or a pharmacy in Australia?
No. KLOW is not a registered medicine and none of its four peptides is stocked by Chemist Warehouse, Priceline or other retail pharmacies. Topical cosmetic serums containing small percentages of GHK-Cu are sold by beauty retailers and some pharmacies, but those are cosmetics; the lyophilised research blend supplied here is a laboratory reagent, not a cosmetic or medicine.

Can Australian compounding pharmacies supply KLOW?
Compounding pharmacies in Australia prepare medicines only for an individual patient on a practitioner's prescription and do not sell peptides to the public. Omega Peptides Australia is not a pharmacy. We supply the lyophilised research blend with a batch COA, strictly for in-vitro laboratory use.

How do you reconstitute KLOW?
Use bacteriostatic water. Swab the stopper, then add the chosen volume of water slowly down the inside wall of the vial so it runs onto the powder rather than jetting into it. Swirl gently until the solution is clear, do not shake, because agitation can fragment the peptides. GHK-Cu gives the solution a faint blue tint, which is normal. Label the vial with the date and concentration, refrigerate at 2–8°C and use within 28 days.

How should KLOW be stored?
Keep the lyophilised vial sealed and protected from light and moisture. Short-term storage at 2–8°C is fine; for long-term storage keep it at −20°C and avoid repeated freeze-thaw cycles. After reconstitution, store the solution refrigerated at 2–8°C and use it within 28 days. Let a cold vial reach room temperature before opening it so condensation does not form on the powder.

Where can I buy KLOW in Australia?
Directly from Omega Peptides Australia. Stock is held domestically, orders placed before 12pm are dispatched the same day, and every batch is tested by Janoshik Analytical with the certificate published in our COA library. KLOW can be ordered on this page or browsed with the rest of our research peptides in Australia, including the GLOW blend and the individual GHK-Cu, BPC-157, TB-500 and KPV vials.

What does KLOW cost in Australia?
KLOW is $149.99 for an 80mg vial, or about $1.87 per mg of total peptide. The same quantities bought as individual vials would cost $369.96, so the blend is the lower-cost option for laboratories that want all four peptides. GLOW, the three-peptide version without KPV, is $139.99 for 70mg.

How do I get KLOW online in Australia?
Add the 80mg vial to your cart, add bacteriostatic water if required, and complete checkout. Orders ship from within Australia with tracked domestic delivery and discreet, unbranded packaging. Orders placed before 12pm on a business day are dispatched the same day, and later orders leave the next business day.

Is KLOW legal in Australia?
Omega Peptides Australia supplies KLOW strictly for lawful in-vitro laboratory research. It is not approved by the TGA for human or veterinary use and is not sold as a medicine or supplement. Purchasers are responsible for ensuring their intended use complies with all applicable laws.

What is the difference between KLOW and GLOW?
The only difference is KPV. GLOW contains GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg in a 70mg vial for $139.99. KLOW contains the same three peptides in the same amounts plus 10mg of KPV, for 80mg at $149.99. Choose KLOW when the study design calls for an anti-inflammatory tripeptide alongside the collagen and repair components, and GLOW when it does not.

Is KLOW peptide available in Australia?
Yes. Omega Peptides Australia holds the KLOW 80mg blend in Australian stock as a research-grade lyophilised vial, COA verified, with same-day dispatch before 12pm.

Where can I buy the KLOW blend in Australia?
From an Australian research peptide supplier with domestic stock. Omega Peptides Australia ships KLOW from within Australia on tracked delivery with the batch certificate published.

⚠ For in-vitro research and laboratory use only. Not for human or veterinary use.